Get started
Author

Katsumasa Nagano

Observed name: Nagano Katsumasa
ORCID: 0000-0002-9201-181X
Observed ORCID: 0000-0002-9201-181X
OpenAlex ID: A5026879859
Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
2023 · Katsumasa Nagano, Erina Hata, et al. · Crohn s & Colitis 360 · 10
Association between oral corticosteroid starting dose and the incidence of pneumonia in Japanese patients with ulcerative colitis: a nation-wide claims database study
2024 · Katsuyoshi Matsuoka, Tomoyuki Inoue, et al. · Intestinal Research · 5
PDF
Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial
2022 · Katsumasa Nagano, Yuya Imai, et al. · Inflammatory Intestinal Diseases · 4
PDF
Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
2022 · Katsuyoshi Matsuoka, Katsumasa Nagano, et al. · BMJ Open · 4
PDF
Evaluation of economic burden with biologic treatments in Crohn’s disease patients: A mirror image study using an insurance database in Japan
2021 · Celine Miyazaki, Nagano Katsumasa, et al. · PLoS ONE · 3
PDF
Perceptions and Responses to Diseases among Patients with Inflammatory Bowel Disease: Text Mining Analysis of Posts on a Japanese Patient Community Website
2024 · Eujin Lee, Hiroaki Tsuchiya, et al. · Inflammatory Intestinal Diseases · 1
Using Pre-Study Patient Interviews to Refine Electronic Patient-Reported Outcomes in Clinical Research of Ustekinumab Induction for Ulcerative Colitis (SIRIUS Study)
2026 · Katsumasa Nagano, Shun Emoto, et al. · Advances in Therapy
PDF
Works count: 7
Citation count: 27
H-index: 4
I10-index: 1
Year
Topic
Type